You are here

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Research Center
Los Angeles, California, 90033 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Multiple Myeloma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eligible patients must be at least 18 years of age with a diagnosis of multiple
myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by
the doctor during the investigational drug's treatment.

- The patient's multiple myeloma must have gotten worse during/after previous
chemotherapy was given.

- Any side-effects from prior chemotherapy must have subsided

- Blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria:

Any of the following will exclude patients from study participation:

- indolent or smoldering myeloma or localized plasmacytoma

- hyperviscosity syndrome

- irradiation to 25% or more of bone marrow

- prior high dose chemotherapy with bone marrow or stem cell support

- current participation in other clinical trials

- pregnant or breast-feeding women

- known HIV-positive or AIDS-related illness

- patients planning to have radiation therapy or surgery that would interrupt study
therapy in the next 6 months.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

further examination by the investigator is necessary.

NCT00036140
Pfizer
Completed
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Multiple Myeloma
NCT03269136
All Genders
18+
Years
Multiple Sites
Secondary Progressive Multiple Sclerosis
NCT00146159
All Genders
18+
Years
Multiple Sites
Neoplasms, Thrombocytopenia, Multiple Myeloma, Malignant Lymphoma
NCT00037791
All Genders
18+
Years
Multiple Sites
Relapsing-Remitting Multiple Sclerosis
NCT00228397
All Genders
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
Not Provided
The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.
Not Provided
Interventional
Phase 1
Primary Purpose: Treatment
Multiple Myeloma
Drug: Investigational drug
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria:

  • Eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment.
  • The patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given.
  • Any side-effects from prior chemotherapy must have subsided
  • Blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria:

Any of the following will exclude patients from study participation:

  • indolent or smoldering myeloma or localized plasmacytoma
  • hyperviscosity syndrome
  • irradiation to 25% or more of bone marrow
  • prior high dose chemotherapy with bone marrow or stem cell support
  • current participation in other clinical trials
  • pregnant or breast-feeding women
  • known HIV-positive or AIDS-related illness
  • patients planning to have radiation therapy or surgery that would interrupt study therapy in the next 6 months.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00036140
196-ONC-0100-006
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Not Provided
Pfizer
March 2004

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now